Precipio to distribute HemeScreen® through Fisher Healthcare channel
20 juil. 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
26 avr. 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
26 août 2021 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...
First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada
13 nov. 2018 00h00 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
04 juin 2018 00h30 HE
|
MolecularMD
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and...
MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna
22 déc. 2017 18h02 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Dec. 22, 2017 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a diagnostics company that enables the development and commercialization of precision medicines in...